<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23145040</article-id><article-id pub-id-type="pmc">3493612</article-id><article-id pub-id-type="publisher-id">PONE-D-12-24700</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0048959</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Co-Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Prospective Studies</subject></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Clinical Pharmacology</subject></subj-group></subj-group><subj-group><subject>Gastroenterology and Hepatology</subject></subj-group><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>Hepatitis</subject><subj-group><subject>Hepatitis C</subject></subj-group></subj-group><subj-group><subject>HIV</subject><subj-group><subject>HIV diagnosis and management</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients</article-title><alt-title alt-title-type="running-head">Low versus Standard-Dose of HCV Treatment</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rivero-Ju&#x000e1;rez</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lopez-Cortes</surname><given-names>Luis F.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Camacho</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Torres-Cornejo</surname><given-names>Almudena</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pineda</surname><given-names>Juan A.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Marquez-Solero</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caruz</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ruiz-Valderas</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Torre-Cisneros</surname><given-names>Julian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gutierrez-Valencia</surname><given-names>Alicia</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rivero</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Cordoba, Spain</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Maimonides Institute for Biomedical Research, Cordoba, Spain</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Enfermedades Infecciosas, Microbiolog&#x000ed;a y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc&#x000ed;o/Consejo Superior de Investigaciones Cient&#x000ed;ficas/Universidad de Sevilla, Seville, Spain</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Unit of Infectious Diseases, Hospital Universitario Virgen de la Victoria, Malaga, Spain</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Immunogenetics Unit, Faculty of Sciences, Universidad de Ja&#x000e9;n, Jaen, Spain</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Ho</surname><given-names>Wenzhe</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Temple University School of Medicine, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>ariveror@gmail.com</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>AR has received consulting fees from Bristol-Myers Squibb, Abbott, Gilead, Roche and Boehringer Ingelheim. JAP has received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott, Gilead, Merck Sharp &#x00026; Dohme, Janssen-Cilag and Boehringer Ingelheim. LFLC has received funds for speaking at symposia organized on behalf of Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithkline, Gilead Sciences, MSD, Janssen-Cilag S. A., and Viiv Healthcare. They have received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott and Boehringer Ingelheim, and lecture fees from GlaxoSmithKline, Roche, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim and Schering-Plough. The remaining authors have no conflicts of interest to declare. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: ARJ LFLC AR. Performed the experiments: ARJ LFLC JAP A. Camacho MMS AR. Analyzed the data: ARJ AR. Contributed reagents/materials/analysis tools: AR ARJ LFLC A. Camacho ATC JAP MMS A. Caruz RRV JTC AGV. Wrote the paper: ARJ AR. Critical discussion of the manuscript: AR ARJ LFLC A. Camacho ATC JAP MMS A. Caruz RRV JTC AGV.</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>8</day><month>11</month><year>2012</year></pub-date><volume>7</volume><issue>11</issue><elocation-id>e48959</elocation-id><history><date date-type="received"><day>16</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>2</day><month>10</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Rivero-Jurez et al</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Rivero-Jurez et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-&#x003b1;2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment.</p></sec><sec><title>Methods</title><p>Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-na&#x000ef;ve HCV genotype 3 patients with HIV co-infection. The Standard Dose Group (SDG) included patients who received Peg-IFN at 180 &#x000b5;g/per week with a weight-adjusted dose of ribavirin; Low-Dose Group (LDG) patients received Peg-IFN at 135 &#x000b5;g/per week with 800 mg/day ribavirin. The effect of IL28B genotype on HCV viral decline was evaluated in both groups. HCV viral decline was analyzed using a multivariate linear regression model.</p></sec><sec><title>Results</title><p>One hundred and six patients were included: 48 patients in the SDG and 58 in the LDG. HCV viral decline for patients in the LDG was less than for those in the SDG (week 1&#x02236;1.72&#x000b1;0.74 log<sub>10</sub> IU/mL <italic>versus</italic> 1.78&#x000b1;0.67 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.827; week 2&#x02236;2.3&#x000b1;0.89 log<sub>10</sub> IU/mL <italic>versus</italic> 3.01&#x000b1;1.02 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.013; week 4&#x02236;3.52&#x000b1;1.2 log<sub>10</sub> IU/mL <italic>versus</italic> 4.09&#x000b1;1.1 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.005). The linear regression model identified the Peg-IFN/RBV dose as an independent factor for HCV viral decline at week 4.</p></sec><sec><title>Conclusions</title><p>Our results showed that HCV viral decline was less for patients in the low-dose group compared to those receiving the standard dose. Until a randomized clinical trial is conducted, clinicians should be cautious about using lower doses of Peg-IFN/RBV in HIV/HCV genotype 3 co-infected patients.</p></sec></abstract><funding-group><funding-statement>This work was partly supported by grants from the Fundaci&#x000f3;n Progreso y Salud, Consejer&#x000ed;a de Salud de la Junta de Andaluc&#x000ed;a (grants for health research projects: refs. 0036/2010, PI-0247-2010 and PI-0208 and 0124/2008) and the Spanish Health Ministry (ISCIII-RETIC RD06/006, and projects PI10/0164 and PI10/01232). AR is the recipient of a research extension grant from the Fundaci&#x000f3;n Progreso y Salud, Consejer&#x000ed;a de Salud de la Junta de Andaluc&#x000ed;a (Reference AI-0011-2010); JAP is the recipient of extension grant from the Instituto de Salud Carlos III (grant number Programa-I3SNS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The best determinant of response to hepatitis C virus (HCV) treatment using pegylated-interferon (Peg-IFN) in combination with ribavirin (Peg-IFN/RBV) is the HCV genotype itself. Rates of sustained virological response (SVR) in genotypes 1 or 4 HCV patients co-infected with HIV vary between 17 and 46% in different studies, while for genotype 3 HCV/HIV co-infected patients these values range between 43 and 71% <xref rid="pone.0048959-Chung1" ref-type="bibr">[1]</xref>, <xref rid="pone.0048959-Torriani1" ref-type="bibr">[2]</xref>. The higher treatment response rate for genotype 3 HCV patients is due the higher rate of HCV viral clearance in the first weeks of therapy <xref rid="pone.0048959-RiveroJuarez1" ref-type="bibr">[3]</xref>. On the other hand, it has also been observed that HCV genotype 3 patients progress more rapidly to advanced stages of liver fibrosis and hepatic steatosis and are at a significantly higher risk of developing hepatocellular carcinoma <xref rid="pone.0048959-Bochoud1" ref-type="bibr">[4]</xref>&#x02013;<xref rid="pone.0048959-Nkontchou1" ref-type="bibr">[6]</xref>. For these reasons, patients infected with HCV genotype 3 constitute a population which requires the early implementation of treatment.</p><p>The current recommended treatment for genotype 3 HCV/HIV co-infected patients is 48 weeks with Peg-IFN-&#x003b1;2a or Peg-IFN-&#x003b1;2b (180 &#x000b5;g/kg and 1.5 &#x000b5;g/kg per week, respectively) combined with ribavirin (weight-adjusted) <xref rid="pone.0048959-Ghany1" ref-type="bibr">[7]</xref>, <xref rid="pone.0048959-Sulkowski1" ref-type="bibr">[8]</xref>. However, neither duration of treatment nor drug dose have been clearly optimized. For genotype 3 HCV monoinfected patients, the recommended length of treatment is 24 weeks, and even 12&#x02013;16 weeks for patients achieving rapid virological response (RVR), and lower doses of Peg-IFN/RBV have been shown to achieve similar SVR rates to the standard dose <xref rid="pone.0048959-McHutchison1" ref-type="bibr">[9]</xref>&#x02013;<xref rid="pone.0048959-Weiland1" ref-type="bibr">[11]</xref>. However, because of the different responses to treatment, more rapid progression to liver fibrosis, interaction with antiretroviral treatment drugs and immunological characteristics, the results cannot be extrapolated to HIV/HCV co-infected patients <xref rid="pone.0048959-Soriano1" ref-type="bibr">[12]</xref>, <xref rid="pone.0048959-Operskalski1" ref-type="bibr">[13]</xref>.</p><p>Early viral kinetics gives clinicians valuable information about the outcome of HCV treatment. Several studies have shown that HCV viral decay in the first weeks after start of treatment can help identify which patients will respond to treatment and which will not <xref rid="pone.0048959-Suzuki1" ref-type="bibr">[14]</xref>&#x02013;<xref rid="pone.0048959-DuranteMangoni1" ref-type="bibr">[19]</xref>. HCV viral decline during the first weeks of treatment is also useful for analyzing the effects of different drug doses, including the impact on HCV clearance.</p><p>The aim of this study was to analyze the different impacts of standard and lower-than- standard dose Peg-IFN-&#x003b1;2a/RBV therapy on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks after start of treatment.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Patients, Study Design and Treatment Regimen</title><p>Two groups of HIV/HCV genotype 3 co-infected patients who were na&#x000ef;ve to HCV treatment were included in the study.</p><p>The Standard Dose Group (SDG) included patients enrolled in a prospective study designed to evaluate the efficacy of a treatment strategy for chronic hepatitis C genotype 3, who were administered Peg-IFN-&#x003b1;2a at 180 &#x000b5;g/per week combined with a weight-adjusted dose of ribavirin (1000 mg/day for &#x0003c;75 kg, 1200 mg/day for &#x02265;75 kg); length of treatment (24 or 48 weeks) was determined according to whether or not RVR was achieved<monospace>.</monospace>
</p><p>The Low Dose Group (LDG) included patients enrolled in an open-label, single-arm clinical trial (Reference: NCT00553930) evaluating the efficacy of Peg-IFN-&#x003b1;2a at a dose of 135 &#x000b5;g/per week combined with a daily ribavirin dose of 800 mg.</p></sec><sec id="s2b"><title>Ethical Aspects</title><p>The SDG study was designed and carried out according to the Helsinki declaration and was approved by the Ethics Committee of the Hospital Reina Sofia of Cordoba. (Reference: NCT00553930). All patients were informed and signed an informed consent form before participating in the study. The protocol of the LDG trial and supporting CONSORT checklist are available as supporting information; see <xref rid="pone.0048959-LopezCortes1" ref-type="bibr">[20]</xref>. The study protocol was approved by the Agencia Espa&#x000f1;ola del Medicamento and a central ethics committee (Comit&#x000e9; Auton&#x000f3;mico de Ensayos Cl&#x000ed;nicos, Consejer&#x000ed;a de Salud, Junta de Andaluc&#x000ed;a). The study was conducted according to the Declaration of Helsinki and current guidelines on Good Clinical Practices. This trial is registered at NIH register (ClinicalTrials.gov: NCT00553930) and EMEA (N&#x000b0;EudraCT: 2007-000814-35).</p></sec><sec id="s2c"><title>Data Collection</title><p>Host, clinical and virological characteristics were collected. Fibrosis stage was determined by biopsy or liver transient elastography (FibroScan&#x000ae;, Echosen. Paris). Significant fibrosis was defined as a METAVIR fibrosis score of F2&#x02013;F4 in liver biopsy or a liver stiffness value of &#x02265;8.9 kPa <xref rid="pone.0048959-Macias1" ref-type="bibr">[21]</xref>.</p></sec><sec id="s2d"><title>Virological Evaluation</title><p>Plasma HCV RNA load measurements were conducted at baseline and weeks 1, 2 and 4, using a quantitative PCR assay (Cobas TaqMan, Roche Diagnostic Systems Inc., Pleasanton, CA, USA) and using a detection limit of 15 IU/mL. Viral load was expressed as log<sub>10</sub>IU/mL.</p></sec><sec id="s2e"><title>IL28B Genotyping</title><p>DNA was extracted using the automated MagNA Pure DNA extraction method (Roche Diagnostics Corporation. Indianapolis, IN 46250, USA). Single nucleotide polymorphism (SNP) rs129679860, located 3 kilobases upstream of the IL28B, and in strong linkage disequilibrium with a non-synonymous coding variant in the IL28B gene (213A&#x0003e;G, K70R; rs81031142), was genotyped. Genotyping was carried out using a custom TAQMAN assay (Applied Biosystems, Foster City, California, USA) on DNA isolated from whole blood samples, on a Stratagene MX3005 thermocycler with MXpro software (Stratagene, La Jolla, California, USA), following the manufacturer&#x02019;s instructions. The researchers responsible for genotyping were blinded to other patient data. The IL28B genotype was defined as CC or non-CC (TT/CT).</p></sec><sec id="s2f"><title>Statistical Analysis</title><p>Continuous variables were expressed as mean &#x000b1; standard deviation or median (Q1&#x02013;Q3) and were analyzed by the Student&#x02019;s <italic>t</italic> test, Mann-Whitney <italic>U</italic>-test or Kruskal-Wallis test. Categorical variables were expressed as numbers of cases (percentage). Frequencies were compared using the &#x003c7;<sup>2</sup> test or Fisher&#x02019;s exact test. Significance was defined as a <italic>p</italic> value of less than 0.05. Plasma HCV RNA decline, according to SDG and LDG dose, was analyzed from baseline to weeks 1, 2 and 4. The effect of IL28B genotype on HCV viral decline was also analyzed in both treatment groups. Patients presenting an undetectable HCV viral load at any time point during the study were excluded when calculating reduction of HCV RNA levels at a later time. A multivariate linear regression model was used to analyze HCV viral decline between baseline and the various time points. In addition, two linear regression models of HCV viral decline from baseline to the different time points were analyzed according to treatment group. The analysis was performed using the SPSS statistical software package, version 18.0 (IBM Corporation, Somers, NY, USA).</p></sec></sec><sec id="s3"><title>Results</title><p>One hundred and six HIV/HCV genotype 3 co-infected patients were included in the study. Forty-eight (45.3%) patients were included in the SDG and 58 (54.7%) in the LDG. The baseline population characteristics of the two groups are shown in <xref ref-type="table" rid="pone-0048959-t001">Table 1</xref>
<monospace>.</monospace>
</p><table-wrap id="pone-0048959-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0048959.t001</object-id><label>Table 1</label><caption><title>Baseline Population Characteristics.</title></caption><alternatives><graphic id="pone-0048959-t001-1" xlink:href="pone.0048959.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">SDG</td><td align="left" rowspan="1" colspan="1">LDG</td><td align="left" rowspan="1" colspan="1">P</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male. N (%)</td><td align="left" rowspan="1" colspan="1">39 (81.2)</td><td align="left" rowspan="1" colspan="1">51 (87.9)</td><td align="left" rowspan="1" colspan="1">0.379</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years). Mean (SD)</td><td align="left" rowspan="1" colspan="1">40.4 (8.86)</td><td align="left" rowspan="1" colspan="1">43.6 (5.37)</td><td align="left" rowspan="1" colspan="1">0.612</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of HAART, n (%)</td><td align="left" rowspan="1" colspan="1">45 (93.7)</td><td align="left" rowspan="1" colspan="1">52 (89.6)</td><td align="left" rowspan="1" colspan="1">0.588</td></tr><tr><td align="left" rowspan="1" colspan="1">AIDS diagnosis in the past, n (%)</td><td align="left" rowspan="1" colspan="1">13 (27.1)</td><td align="left" rowspan="1" colspan="1">10 (17.2)</td><td align="left" rowspan="1" colspan="1">0.213</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline CD4 count (cells/mm<sup>3</sup>). mean (SD)</td><td align="left" rowspan="1" colspan="1">479.9 (234.7)</td><td align="left" rowspan="1" colspan="1">496.5 (266.4)</td><td align="left" rowspan="1" colspan="1">0.743</td></tr><tr><td align="left" rowspan="1" colspan="1">PIDU, n (%)</td><td align="left" rowspan="1" colspan="1">43 (89.5)</td><td align="left" rowspan="1" colspan="1">48 (82.7)</td><td align="left" rowspan="1" colspan="1">0.454</td></tr><tr><td align="left" rowspan="1" colspan="1">HCV baseline viral load (log<sub>10</sub> IU/mL). Mean (SD)</td><td align="left" rowspan="1" colspan="1">5.72 (0.75)</td><td align="left" rowspan="1" colspan="1">5.51 (1)</td><td align="left" rowspan="1" colspan="1">0.247</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver fibrosis stage F2&#x02013;F4. n (%)</td><td align="left" rowspan="1" colspan="1">32 (66.6)</td><td align="left" rowspan="1" colspan="1">33 (56.9)</td><td align="left" rowspan="1" colspan="1">0.277</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver Cirrhosis. n (%)</td><td align="left" rowspan="1" colspan="1">12 (25)</td><td align="left" rowspan="1" colspan="1">21 (36.2)</td><td align="left" rowspan="1" colspan="1">0.253</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (IU/L). Mean (SD)</td><td align="left" rowspan="1" colspan="1">80.3 (47.7)</td><td align="left" rowspan="1" colspan="1">91 (57)</td><td align="left" rowspan="1" colspan="1">0.409</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (IU/L). Mean (SD)</td><td align="left" rowspan="1" colspan="1">65.5 (35.2)</td><td align="left" rowspan="1" colspan="1">79.9 (33)</td><td align="left" rowspan="1" colspan="1">0.541</td></tr><tr><td align="left" rowspan="1" colspan="1">Total fasting cholesterol (mg/dL). Mean (SD)</td><td align="left" rowspan="1" colspan="1">156.1 (40.4)</td><td align="left" rowspan="1" colspan="1">147 (37)</td><td align="left" rowspan="1" colspan="1">0.325</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mg/dL). Mean (SD)</td><td align="left" rowspan="1" colspan="1">86.8 (33.6)</td><td align="left" rowspan="1" colspan="1">76 (29)</td><td align="left" rowspan="1" colspan="1">0.147</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count (10<sup>3</sup>/&#x000b5;L). Mean (SD)</td><td align="left" rowspan="1" colspan="1">183 (65)</td><td align="left" rowspan="1" colspan="1">176 (68)</td><td align="left" rowspan="1" colspan="1">0.654</td></tr><tr><td align="left" rowspan="1" colspan="1">IL28B-CC genotype. N (%)</td><td align="left" rowspan="1" colspan="1">13 (43.4)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">24 (53.3)<sup>&#x02021;</sup>
</td><td align="left" rowspan="1" colspan="1">0.409</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Standard drug dose group (SDG); low drug dose group (LDG); human immunodeficiency virus (HIV); highly active antiretroviral treatment (HAART); acquired immunodeficiency syndrome criteria in the past (AIDS); previous intravenous drug user (PIDU); hepatitis C virus (HCV); interleukin 28B (IL28B). <sup>&#x02020;</sup>Available for 30 patients. <sup>&#x02021;</sup>Available for 45 patients.</p></fn></table-wrap-foot></table-wrap><sec id="s3a"><title>HCV Viral Decline According to Treatment Group</title><p>HCV viral decline of patients given the lower dose treatment was less than for those in the SDG, at weeks 2 and 4 after start of treatment, although not at week 1 (week 1&#x02236;1.72&#x000b1;0.74 log<sub>10</sub> IU/mL <italic>versus</italic> 1.78&#x000b1;0.67 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.827; week 2&#x02236;2.3&#x000b1;0.89 log<sub>10</sub> IU/mL <italic>versus</italic> 3.01&#x000b1;1.02 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.013; week 4&#x02236;3.52&#x000b1;1.2 log<sub>10</sub> IU/mL <italic>versus</italic> 4.09&#x000b1;1.1 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.005) (<xref ref-type="fig" rid="pone-0048959-g001">Figure 1</xref>). The multivariate linear regression models of factors associated with HCV viral decline at weeks 1, 2 and 4 showed that the steeper and sustained HCV viral decline from week 2 to week 4 was associated with a lower baseline HCV RNA viral load and with patients in the SDG (<xref ref-type="table" rid="pone-0048959-t002">Table 2</xref>). IL28B-CC and HCV viral decline were not associated.</p><fig id="pone-0048959-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0048959.g001</object-id><label>Figure 1</label><caption><title>Mean HCV viral decline between baseline and weeks 1, 2 and 4 for the standard drug dose group (SDG) and the low drug dose group (LDG).</title></caption><graphic xlink:href="pone.0048959.g001"/></fig><table-wrap id="pone-0048959-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0048959.t002</object-id><label>Table 2</label><caption><title>Multivariate linear regression model of HCV viral decline between baseline and weeks 1, 2 and 4 after start of treatment.</title></caption><alternatives><graphic id="pone-0048959-t002-2" xlink:href="pone.0048959.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="5" align="left" rowspan="1">HCV decline at week 1</td></tr><tr><td align="left" rowspan="1" colspan="1">Factor</td><td align="left" rowspan="1" colspan="1">Condition</td><td colspan="2" align="left" rowspan="1">B</td><td align="left" rowspan="1" colspan="1">P</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment Group</td><td align="left" rowspan="1" colspan="1">SDG</td><td colspan="2" align="left" rowspan="1">&#x02212;0.175</td><td align="left" rowspan="1" colspan="1">0.327</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline HCV viral load (log<sub>10</sub> IU/mL)</td><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">0.059</td><td align="left" rowspan="1" colspan="1">0.637</td></tr><tr><td align="left" rowspan="1" colspan="1">Significant liver fibrosis stage</td><td align="left" rowspan="1" colspan="1">Yes</td><td colspan="2" align="left" rowspan="1">&#x02212;0.247</td><td align="left" rowspan="1" colspan="1">0.676</td></tr><tr><td align="left" rowspan="1" colspan="1">IL28B genotype</td><td align="left" rowspan="1" colspan="1">Non-CC</td><td colspan="2" align="left" rowspan="1">0.296</td><td align="left" rowspan="1" colspan="1">0.113</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>HCV decline at week 2</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Factor</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Condition</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>B</bold>
</td><td colspan="2" align="left" rowspan="1">
<bold>P</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment Group</td><td align="left" rowspan="1" colspan="1">SDG</td><td align="left" rowspan="1" colspan="1">0.274</td><td colspan="2" align="left" rowspan="1">
<bold>0.037</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline HCV viral load</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.329</td><td colspan="2" align="left" rowspan="1">
<bold>0.026</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Significant liver fibrosis stage</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">&#x02212;0.113</td><td colspan="2" align="left" rowspan="1">0.340</td></tr><tr><td align="left" rowspan="1" colspan="1">IL28B genotype</td><td align="left" rowspan="1" colspan="1">Non-CC</td><td align="left" rowspan="1" colspan="1">&#x02212;0.103</td><td colspan="2" align="left" rowspan="1">0.551</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>HCV decline at week 4</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Factor</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Condition</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>B</bold>
</td><td colspan="2" align="left" rowspan="1">
<bold>P</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment Group</td><td align="left" rowspan="1" colspan="1">SDG</td><td align="left" rowspan="1" colspan="1">0.335</td><td colspan="2" align="left" rowspan="1">
<bold>0.025</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline HCV viral load</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.339</td><td colspan="2" align="left" rowspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Significant liver fibrosis stage</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">&#x02212;0.180</td><td colspan="2" align="left" rowspan="1">0.092</td></tr><tr><td align="left" rowspan="1" colspan="1">IL28B genotype</td><td align="left" rowspan="1" colspan="1">Non-CC</td><td align="left" rowspan="1" colspan="1">&#x02212;0.041</td><td colspan="2" align="left" rowspan="1">0.791</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>adjusted coefficient (B), hepatitis C virus (HCV), interleukin 28B (IL28B), standard drug dose group (SDG). R<sup>2</sup>&#x0200a;=&#x0200a;0.327.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>HCV Viral Decline According to Treatment Group and IL28B Genotype</title><p>Among SDG patients, there were no differences of HCV viral decline by IL28B genotype at week 1 (1.82&#x000b1;0.91 log<sub>10</sub> IU/mL <italic>versus</italic> 1.74&#x000b1;0.87 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.852), week 2 (3&#x000b1;1.1 log<sub>10</sub> IU/mL <italic>versus</italic> 3.08&#x000b1;1.09 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.807) or week 4 (4.14&#x000b1;0.84 log<sub>10</sub> IU/mL <italic>versus</italic> 4.17&#x000b1;1.06 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.938) (<xref ref-type="fig" rid="pone-0048959-g002">Figure 2A</xref>). Similarly, no differences of HCV viral decline by IL28B genotype were found among LDG patients at week 1 (2.07&#x000b1;0.47 log<sub>10</sub> IU/mL <italic>versus</italic> 1.42&#x000b1;1.08 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.071), week 2 (2.46&#x000b1;0.86 log<sub>10</sub> IU/mL <italic>versus</italic> 2.03&#x000b1;1.35 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.257) or week 4 (3.44&#x000b1;0.94 log<sub>10</sub> IU/mL <italic>versus</italic> 3.26&#x000b1;1.01 log<sub>10</sub> IU/mL, p&#x0200a;=&#x0200a;0.573) (<xref ref-type="fig" rid="pone-0048959-g002">Figure 2B</xref>).</p><fig id="pone-0048959-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0048959.g002</object-id><label>Figure 2</label><caption><title>Mean HCV viral decline by IL28B genotype for the standard dose group (SDG) (<xref ref-type="fig" rid="pone-0048959-g002">
<bold>Figure 2A</bold>
</xref>) and the low-dose group (LDG) (<xref ref-type="fig" rid="pone-0048959-g002">
<bold>Figure 2B</bold>
</xref>).</title></caption><graphic xlink:href="pone.0048959.g002"/></fig><p>Among IL28B-CC genotype patients, HCV viral decline was greater in the SDG than in the LDG at weeks 2 and 4, but not at week 1 (week 1: p&#x0200a;=&#x0200a;0.362; week 2: p&#x0200a;=&#x0200a;0.051; week 4: p&#x0200a;=&#x0200a;0.033). Likewise, HCV viral decline was greater among SDG patients carrying the IL28B non-CC genotype than among their LDG non-CC counterparts, at weeks 2 and 4 (week 1: p&#x0200a;=&#x0200a;0.343; week 2: p&#x0200a;=&#x0200a;0.034; week 4: p&#x0200a;=&#x0200a;0.037).</p></sec><sec id="s3c"><title>Rapid Virological Response Rate</title><p>HCV viral load for 6 (5.6%) patients could not be evaluated at week 4. Of the remaining 100 patients, 66 (66%) achieved RVR: thirty-five (72.9%) in the SDG, and 31 (59.6%) in the LDG (p&#x0200a;=&#x0200a;0.174). RVR rates by treatment group and IL28B genotype are shown in <xref ref-type="table" rid="pone-0048959-t003">Table 3</xref>.</p><table-wrap id="pone-0048959-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0048959.t003</object-id><label>Table 3</label><caption><title>Rapid virological response (RVR) rate by treatment group and IL28B genotype.</title></caption><alternatives><graphic id="pone-0048959-t003-3" xlink:href="pone.0048959.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="left" rowspan="1" colspan="1">IL28B genotype</td><td align="left" rowspan="1" colspan="1">RVR. N (%)</td><td align="left" rowspan="1" colspan="1">P</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SDG</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">9 (40.9)</td><td align="left" rowspan="1" colspan="1">0.748</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Non-CC</td><td align="left" rowspan="1" colspan="1">12 (44.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDG</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">13 (38.2)</td><td align="left" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Non-CC</td><td align="left" rowspan="1" colspan="1">12 (35.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL28B genotype</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Treatment group</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>RVR. N (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>P</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">SDG</td><td align="left" rowspan="1" colspan="1">9 (40.9)</td><td align="left" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LDG</td><td align="left" rowspan="1" colspan="1">13 (38.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-CC</td><td align="left" rowspan="1" colspan="1">SDG</td><td align="left" rowspan="1" colspan="1">12 (44.4)</td><td align="left" rowspan="1" colspan="1">0.221</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LDG</td><td align="left" rowspan="1" colspan="1">12 (35.3)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>Interleukin 28B (IL28B), rapid virological response (RVR), standard drug dose group (SDG), low drug dose group (LDG).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>In our study, HCV viral decay of patients who received low-dose Peg-IFN/RBV treatment was less during the first weeks of treatment than for those receiving the standard Peg-IFN/RBV dose. This finding suggests that a lower Peg-IFN/RBV dose has less antiviral activity than the standard dose.</p><p>High viral decline during the first weeks of treatment leads to a high RVR rate <xref rid="pone.0048959-RiveroJuarez1" ref-type="bibr">[3]</xref>. Several factors have been identified as determining HCV viral decay <xref rid="pone.0048959-RiveroJuarez1" ref-type="bibr">[3]</xref>, <xref rid="pone.0048959-Macias1" ref-type="bibr">[21]</xref>. Our study found that HCV viral decay correlated with Peg-IFN dose in HIV/HCV genotype 3 co-infected patients, with steeper viral decline from week 2 to week 4 in the SDG compared to the LDG. Our study also found that the dose of Peg-IFN administered during treatment was the most important factor affecting HCV viral decline in these patients. RVR rates in our study were also higher in the SDG compared to the LDG (72.9% <italic>versus</italic> 59.6%), although the differences between the two groups were not statistically significant. This point should be interpreted with caution, since a better powered cohort might be required for statistically significant associations, due to the high RVR rate among HCV genotype 3 patients.</p><p>Reducing the dose in drug-based HCV therapy for monoinfected HCV genotype 3 patients has been studied in various clinical trials. Firstly, reducing the dose of Peg-IFN&#x003b1;2a from 180 &#x000b5;g/per week to 135 &#x000b5;g/per week was shown to give similar RVR and SVR rates <xref rid="pone.0048959-McHutchison1" ref-type="bibr">[9]</xref>, <xref rid="pone.0048959-Fried1" ref-type="bibr">[10]</xref>. Secondly, SVR rates did not differ significantly according to whether a lower daily dose or a weight-adjusted dose of ribavirin was used <xref rid="pone.0048959-Pockros1" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pone.0048959-Ferenci1" ref-type="bibr">[24]</xref>. A reduced dose of both drugs is, therefore, applicable to this patient population.</p><p>However, in HCV genotype 3 patients co-infected with HIV, a low-dose Peg-IFN/RBV combination would have a considerable impact, in terms of a high SVR, greater cost savings and fewer adverse events than the standard dose. A previous open-label, single-arm pilot clinical trial involving 58 HCV/HIV co-infected patients receiving low doses of Peg-IFN/RBV found that SVR rates were 58.3% based on intention-to-treat <xref rid="pone.0048959-LopezCortes1" ref-type="bibr">[20]</xref>. The main limitation of this study was the fact that it was not randomized but a single-arm study whose results were compared with those observed in earlier clinical trials The results of the pilot study suggested that a lower Peg-IFN/RBV dose might be as effective as the standard dose, so supporting the design of a randomized controlled trial. There are no data however about the efficacy or safety of standard Peg-IFN/RBV dose compared to a lower-than standard dose.</p><p>To the best of our knowledge, this is the first study to compare the efficacy of HCV viral clearance using low-dose and standard-dose drug therapy in HIV/HCV co-infected patients in the first weeks after treatment starts. Our findings suggest that the antiviral activity of the lower Peg-IFN/RBV dose is weaker than with the standard dose, which does not support equating the two for HIV/HCV co-infected patients. Our results also suggest that HCV viral decline during the first weeks of treatment would be dose-dependent, although the mechanism responsible for the difference is unknown.</p><p>In our study, we found no relation between IL28B genotype and viral decline in either of the regimens evaluated. The positive effect on treatment response associated with the IL28B-CC genotype has only been observed in patients bearing genotype 1/4 <xref rid="pone.0048959-Pineda1" ref-type="bibr">[25]</xref>, <xref rid="pone.0048959-Ge1" ref-type="bibr">[26]</xref>. In fact, a previous study developed by our group reported that variations in IL28B do not have a positive impact on HCV viral decline in the first weeks after start of therapy using a standard drug dose <xref rid="pone.0048959-RiveroJuarez1" ref-type="bibr">[3]</xref>. Nor did IL28B-CC have a positive effect on RVR or SVR at standard or low drug doses in patients bearing genotype 3 <xref rid="pone.0048959-LopezCortes1" ref-type="bibr">[20]</xref>, <xref rid="pone.0048959-Pineda1" ref-type="bibr">[25]</xref>.</p><p>Our study has several limitations. Firstly, our study is not a randomized clinical trial, and the presence of significant bias cannot therefore be ruled out. Secondly, due to the higher RVR rate in HCV genotype 2/3 patients, our study did not have the statistical power to detect differences in RVR rate by drug treatment dose. Thirdly, our study looked at the impact of IL28B by determining only SNP rs12979860, although the impact observed for this is not expected to be different from the other known IL28B SNP (rs8099917).</p><p>In conclusion, our results show that patients who received 135 &#x000b5;g/per week with a 800 mg/day ribavirin dose had less HCV viral decline in the first weeks after treatment started than those who received 180 &#x000b5;g/per week with a weight-adjusted ribavirin dose. The implications of weaker HCV viral decline in terms of treatment outcome are unknown, although it would be expected for a weaker HCV decline to lead to a lower RVR and consequently to a lower SVR. In order to resolve this point, our findings provide justification for the design of a randomized clinical trial to compare the specific efficacy endpoints of the two Peg-IFN/RBV doses in HIV/HCV co-infected patients<monospace>.</monospace> Until such a randomized clinical trial with these specific endpoints is conducted, therefore, clinicians should be cautious about using lower-than-standard Peg-IFN/RBV doses in HIV/HCV genotype 3 co-infected patients.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0048959-Chung1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Chung</surname><given-names>RT</given-names></name>, <name><surname>Andersen</surname><given-names>J</given-names></name>, <name><surname>Volberding</surname><given-names>P</given-names></name>, <name><surname>Robbins</surname><given-names>GK</given-names></name>, <name><surname>Liu</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV coinfected Persons. N Engl J. Med</article-title>. <volume>351</volume>: <fpage>451</fpage>&#x02013;<lpage>459</lpage>.</mixed-citation></ref><ref id="pone.0048959-Torriani1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Torriani</surname><given-names>F</given-names></name>, <name><surname>Rodriguez-Torres</surname><given-names>M</given-names></name>, <name><surname>Rockstroh</surname><given-names>J</given-names></name>, <name><surname>Lissen</surname><given-names>E</given-names></name>, <name><surname>Gonzalez-Garc&#x000ed;a</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med</article-title>. <volume>351</volume>: <fpage>438</fpage>&#x02013;<lpage>450</lpage>.</mixed-citation></ref><ref id="pone.0048959-RiveroJuarez1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Rivero-Juarez</surname><given-names>A</given-names></name>, <name><surname>Camacho</surname><given-names>A</given-names></name>, <name><surname>Perez-Camacho</surname><given-names>I</given-names></name>, <name><surname>Neukam</surname><given-names>K</given-names></name>, <name><surname>Caruz</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother</article-title>. <volume>67</volume>: <fpage>202</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0048959-Bochoud1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Bochoud</surname><given-names>PY</given-names></name>, <name><surname>Cai</surname><given-names>T</given-names></name>, <name><surname>Overbeck</surname><given-names>K</given-names></name>, <name><surname>Bochud</surname><given-names>M</given-names></name>, <name><surname>Dufour</surname><given-names>JF</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol</article-title>. <volume>51</volume>: <fpage>655</fpage>&#x02013;<lpage>66</lpage>.</mixed-citation></ref><ref id="pone.0048959-Probst1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Probst</surname><given-names>A</given-names></name>, <name><surname>Dang</surname><given-names>T</given-names></name>, <name><surname>Bochud</surname><given-names>M</given-names></name>, <name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Negro</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Role of hepatitis C virus genotype 3 in liver fibrosis progression: a systematic review and meta-analysis. J Viral Hepat</article-title>. <volume>18</volume>: <fpage>745</fpage>&#x02013;<lpage>59</lpage>.</mixed-citation></ref><ref id="pone.0048959-Nkontchou1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Nkontchou</surname><given-names>G</given-names></name>, <name><surname>Ziol</surname><given-names>M</given-names></name>, <name><surname>Aout</surname><given-names>M</given-names></name>, <name><surname>Lhabadie</surname><given-names>M</given-names></name>, <name><surname>Baazia</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat</article-title>. <volume>18</volume>: <fpage>e516</fpage>&#x02013;<lpage>22</lpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2893.2011.01441.x"> 10.1111/j.1365-2893.2011.01441.x</ext-link></comment>
</mixed-citation></ref><ref id="pone.0048959-Ghany1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Ghany</surname><given-names>MG</given-names></name>, <name><surname>Strader</surname><given-names>DB</given-names></name>, <name><surname>Thomas</surname><given-names>DL</given-names></name>, <name><surname>Seeff</surname><given-names>LB</given-names></name> (<year>2009</year>) <article-title>Diagnosis, Management and Treatment of Hepatitis C: An update. AASLD Practice Guidelines. Hepatology</article-title>. <volume>49</volume>: <fpage>1335</fpage>&#x02013;<lpage>1374</lpage>.</mixed-citation></ref><ref id="pone.0048959-Sulkowski1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Sulkowski</surname><given-names>MS</given-names></name> (<year>2008</year>) <article-title>Viral hepatitis and HIV coinfection. J Hepatol</article-title>. <volume>48</volume>: <fpage>353</fpage>&#x02013;<lpage>367</lpage>.</mixed-citation></ref><ref id="pone.0048959-McHutchison1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>McHutchison</surname><given-names>JG</given-names></name>, <name><surname>Lawitz</surname><given-names>EJ</given-names></name>, <name><surname>Shiffman</surname><given-names>ML</given-names></name>, <name><surname>Muir</surname><given-names>AJ</given-names></name>, <name><surname>Galler</surname><given-names>GW</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med</article-title>. <volume>361</volume>: <fpage>580</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="pone.0048959-Fried1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Fried</surname><given-names>MW</given-names></name>, <name><surname>Shiffman</surname><given-names>ML</given-names></name>, <name><surname>Reddy</surname><given-names>KR</given-names></name>, <name><surname>Smith</surname><given-names>C</given-names></name>, <name><surname>Marinos</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med</article-title>. <volume>347</volume>: <fpage>975</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation></ref><ref id="pone.0048959-Weiland1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Weiland</surname><given-names>O</given-names></name>, <name><surname>Hollander</surname><given-names>A</given-names></name>, <name><surname>Mattson</surname><given-names>L</given-names></name>, <name><surname>Glaumann</surname><given-names>H</given-names></name>, <name><surname>Lindahl</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat</article-title>. <volume>15</volume>: <fpage>641</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0048959-Soriano1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Soriano</surname><given-names>V</given-names></name>, <name><surname>Vispo</surname><given-names>E</given-names></name>, <name><surname>Labarga</surname><given-names>P</given-names></name>, <name><surname>Medrano</surname><given-names>J</given-names></name>, <name><surname>Barreiro</surname><given-names>P</given-names></name> (<year>2010</year>) <article-title>Viral hepatitis and HIV co-infection. Antiviral Res</article-title>. <volume>85</volume>: <fpage>303</fpage>&#x02013;<lpage>315</lpage>.</mixed-citation></ref><ref id="pone.0048959-Operskalski1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Operskalski</surname><given-names>E</given-names></name>, <name><surname>Kovacs</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>HIV/HCV Co-infection: Pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep</article-title>. <volume>8</volume>: <fpage>12</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="pone.0048959-Suzuki1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Suzuki</surname><given-names>H</given-names></name>, <name><surname>Kakizaki</surname><given-names>S</given-names></name>, <name><surname>Horiguchi</surname><given-names>N</given-names></name>, <name><surname>Ichikawa</surname><given-names>T</given-names></name>, <name><surname>Sato</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Clinical characteristics of null responders to Peg-IFN&#x003b1;2b/ribavirin therapy for chronic hepatitis C. WJH</article-title>. <volume>2</volume>: <fpage>401</fpage>&#x02013;<lpage>405</lpage>.</mixed-citation></ref><ref id="pone.0048959-Boulestin1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Boulestin</surname><given-names>A</given-names></name>, <name><surname>Kamar</surname><given-names>N</given-names></name>, <name><surname>Sandres-Saune</surname><given-names>K</given-names></name>, <name><surname>Legrand-Abravanel</surname><given-names>F</given-names></name>, <name><surname>Alric</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Twenty-four kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Medical Virology</article-title>. <volume>78</volume>: <fpage>365</fpage>&#x02013;<lpage>371</lpage>.</mixed-citation></ref><ref id="pone.0048959-Nomura1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Nomura</surname><given-names>H</given-names></name>, <name><surname>Mitagi</surname><given-names>Y</given-names></name>, <name><surname>Tanimoto</surname><given-names>H</given-names></name>, <name><surname>Ishibashi</surname><given-names>H</given-names></name> (<year>2009</year>) <article-title>Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C. J Viral Hepat</article-title>. <volume>16</volume>: <fpage>346</fpage>&#x02013;<lpage>351</lpage>.</mixed-citation></ref><ref id="pone.0048959-Milan1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Milan</surname><given-names>M</given-names></name>, <name><surname>Boninsegna</surname><given-names>S</given-names></name>, <name><surname>Scribano</surname><given-names>S</given-names></name>, <name><surname>Lobello</surname><given-names>S</given-names></name>, <name><surname>Fagiuoli</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients? Infection</article-title>. <volume>40</volume>: <fpage>173</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0048959-Parruti1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Parruti</surname><given-names>G</given-names></name>, <name><surname>Polilli</surname><given-names>E</given-names></name>, <name><surname>Sozio</surname><given-names>F</given-names></name>, <name><surname>Cento</surname><given-names>V</given-names></name>, <name><surname>Pieri</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Rapid Prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48 h after the start of treatment with pegylated interferon and ribavirin. Antiviral Research</article-title>. <volume>88</volume>: <fpage>124</fpage>&#x02013;<lpage>127</lpage>.</mixed-citation></ref><ref id="pone.0048959-DuranteMangoni1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Durante-Mangoni</surname><given-names>E</given-names></name>, <name><surname>Zampino</surname><given-names>R</given-names></name>, <name><surname>Portella</surname><given-names>G</given-names></name>, <name><surname>Adinolfi</surname><given-names>LE</given-names></name>, <name><surname>Utili</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis</article-title>. <volume>49</volume>: <fpage>498</fpage>&#x02013;<lpage>506</lpage>.</mixed-citation></ref><ref id="pone.0048959-LopezCortes1"><label>20</label><mixed-citation publication-type="journal">
<collab>Lopez-Cortes LF, Ruiz-Valderas R, Jimenez-Jimenez L, Gonz&#x000e1;lez-Escribano MF, Torres-Cornejo A, <italic>et al</italic>; on behalf of the Grupo para el estudio de las hepatitis v&#x000ed;ricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)</collab> (<year>2012</year>) <article-title>Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-&#x003b1;-2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. Plos ONE</article-title>. <volume>7</volume>: <fpage>e28115</fpage> Doi:10.1371/journal.pone.0028115.</mixed-citation></ref><ref id="pone.0048959-Macias1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Macias</surname><given-names>J</given-names></name>, <name><surname>Recio</surname><given-names>E</given-names></name>, <name><surname>Vispo</surname><given-names>E</given-names></name>, <name><surname>Rivero</surname><given-names>A</given-names></name>, <name><surname>L&#x000f3;pez-Cort&#x000e9;s</surname><given-names>LF</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Application of transient elastometry to differentiate mild from moderate to severe fibrosis in HIV/HCV co-infected patients. J Hepatol</article-title>. <volume>49</volume>: <fpage>916</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="pone.0048959-Pockros1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Pockros</surname><given-names>PJ</given-names></name>, <name><surname>Carithers</surname><given-names>R</given-names></name>, <name><surname>Desmond</surname><given-names>P</given-names></name>, <name><surname>Dhumeaux</surname><given-names>D</given-names></name> (<year>2004</year>) <collab>PEGASYS International Study Group, <italic>et al</italic></collab> (<year>2004</year>) <article-title>Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol</article-title>. <volume>99</volume>: <fpage>971</fpage>&#x02013;<lpage>81</lpage>.</mixed-citation></ref><ref id="pone.0048959-Jacobson1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Jacobson</surname><given-names>IM</given-names></name>, <name><surname>Brown</surname><given-names>RS</given-names></name>, <name><surname>Freilich</surname><given-names>B</given-names></name>, <name><surname>Afdhal</surname><given-names>N</given-names></name> (<year>2007</year>) <collab>WIN-R Study Group, <italic>et al</italic></collab> (<year>2007</year>) <article-title>Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial</article-title>. <source>Hepatology</source>
<volume>46</volume>: <fpage>971</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">17894303</pub-id></mixed-citation></ref><ref id="pone.0048959-Ferenci1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Ferenci</surname><given-names>P</given-names></name>, <name><surname>Brunner</surname><given-names>H</given-names></name>, <name><surname>Laferl</surname><given-names>H</given-names></name>, <name><surname>Scherzer</surname><given-names>TM</given-names></name> (<year>2008</year>) <collab>Austrian Hepatitis Study Group, <italic>et al</italic></collab> (<year>2008</year>) <article-title>A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotype 2 and 3. Hepatology</article-title>. <volume>47</volume>: <fpage>1816</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="pone.0048959-Pineda1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Pineda</surname><given-names>JA</given-names></name>, <name><surname>Caruz</surname><given-names>A</given-names></name>, <name><surname>Rivero</surname><given-names>A</given-names></name>, <name><surname>Neukam</surname><given-names>K</given-names></name>, <name><surname>Salas</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis</article-title>. <volume>51</volume>: <fpage>788</fpage>&#x02013;<lpage>95</lpage>.</mixed-citation></ref><ref id="pone.0048959-Ge1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Ge</surname><given-names>D</given-names></name>, <name><surname>Fellay</surname><given-names>J</given-names></name>, <name><surname>Thompson</surname><given-names>AJ</given-names></name>, <name><surname>Simon</surname><given-names>JS</given-names></name>, <name><surname>Shianna</surname><given-names>KV</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature</article-title>. <volume>461</volume>: <fpage>399</fpage>&#x02013;<lpage>401</lpage>.</mixed-citation></ref></ref-list></back></article>